1. Academic Validation
  2. Global Reactivity Profiling of the Catalytic Lysine in Human Kinome for Covalent Inhibitor Development

Global Reactivity Profiling of the Catalytic Lysine in Human Kinome for Covalent Inhibitor Development

  • Angew Chem Int Ed Engl. 2024 Mar 18;63(12):e202316394. doi: 10.1002/anie.202316394.
Guanghui Tang 1 Wei Wang 2 Chengjun Zhu 3 Huisi Huang 3 Peng Chen 2 Xuan Wang 2 Manyi Xu 4 Jie Sun 2 Chong-Jing Zhang 4 Qicai Xiao 2 Liqian Gao 2 Zhi-Min Zhang 3 Shao Q Yao 1
Affiliations

Affiliations

  • 1 Department of Chemistry, National University of Singapore, Singapore, 117543, Singapore.
  • 2 School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen, 518107, China.
  • 3 School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, 510632, China.
  • 4 State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chi-nese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
Abstract

Advances in targeted covalent inhibitors (TCIs) have been made by using lysine-reactive chemistries. Few aminophiles possessing balanced reactivity/stability for the development of cell-active TCIs are however available. We report herein lysine-reactive activity-based probes (ABPs; 2-14) based on the chemistry of aryl fluorosulfates (ArOSO2 F) capable of global reactivity profiling of the catalytic lysine in human kinome from mammalian cells. We concurrently developed reversible covalent ABPs (15/16) by installing salicylaldehydes (SA) onto a promiscuous kinase-binding scaffold. The stability and amine reactivity of these probes exhibited a broad range of tunability. X-ray crystallography and mass spectrometry (MS) confirmed the successful covalent engagement between ArOSO2 F on 9 and the catalytic lysine of Src kinase. Chemoproteomic studies enabled the profiling of >300 endogenous kinases, thus providing a global landscape of ligandable catalytic lysines of the kinome. By further introducing these aminophiles into VX-680 (a noncovalent inhibitor of AURKA kinase), we generated novel lysine-reactive TCIs that exhibited excellent in vitro potency and reasonable cellular activities with prolonged residence time. Our work serves as a general guide for the development of lysine-reactive ArOSO2 F-based TCIs.

Keywords

arylfluorosulfate; catalytic lysine; cell-active; click chemistry; covalent inhibitor; kinase.

Figures
Products